Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
Katja Weisel(Universität Hamburg), Tom Martin(UCSF Helen Diller Family Comprehensive Cancer Center), Fevzi Yalniz, Joris Diels(Janssen (Belgium)), Sundar Jagannath(Mount Sinai Hospital), Suzy Van Sanden(Janssen (Belgium)), Tonia Nesheiwat, Carolyn C. Jackson(Centro de Investigación del Cáncer), Jesús G. Berdeja(Tennessee Oncology), Arnob Banerjee(Johnson & Johnson (United States)), Jordan M. Schecter(Centro de Investigación del Cáncer), William Deraedt(Janssen (Belgium)), Tzu‐Min Yeh(Centro de Investigación del Cáncer), Martin Vogel(Janssen (United States)), Amrita Krishnan(City of Hope), Satish Valluri(Janssen (United States)), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center)
Cited by 17
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k